Recent cytogenetic studies indicated that loss of the long arm of chromosome 10 is a frequent event in small cell lung cancer (SCLC) and that a common region of the deletion is at 10q24-qter, which suggests the presence of a tumor-suppressor gene there. To map precise tumorsuppressor loci on the chromosome arm for further positional cloning eorts, we tested 46 primary SCLCs using microsatellite analysis. By analysing 11 highly polymorphic microsatellite markers located in 10q23-q26, we found that at least 78% (36/46) of the tumors exhibited loss of heterozygosity (LOH) at 10q with at least two distinct minimally deleted regions. LOH at one region (10q24) was found in at least 74% (32/43) of informative cases with a minimally deleted region between D10S198 and D10S192 (about 2 cM); LOH at another region (10q24-q25) was observed in at least 66% (29/44) of informative tumors with a minimally deleted region between D10S221 and D10S587 (about 11 cM). LOH at both regions or across both regions was observed in at least 52% (24/46) of the tumors tested. However, no mutations or homozygous deletions were found in the coding region of MXI1, a candidate tumor suppressor gene at 10q24-q25, in a panel of SCLC cell lines. Our data demonstrate that at least two tumorsuppressor loci exist on 10q and that they may play an important role in SCLC tumorigenesis.
Lung cancer is the leading cause of cancer death in the United States, and small cell lung cancer (SCLC) accounts for more than 20% of lung cancer cases. This tumor type carries an extremely poor prognosis (Parker et al., 1997) . SCLC is believed to develop through a multistep process in which genetic alterations are accumulated, promoting tumorigenesis. Inactivation of tumor-suppressor genes plays an important role in this process and frequently involves loss of one of the alleles and mutations in the other allele (Nowell, 1976; Fearon and Vogelstein, 1990) . Loss of heterozygosity (LOH) was frequently observed at 3p, 5q, 9p, 13q and 17p in SCLC (Sozzi et al., 1996; Hosoe et al., 1994; Merlo et al., 1994; Mori et al., 1990; Miller et al., 1992) . Consistently, frequent alterations of candidate tumor-suppressor genes located on many of these chromosome arms were documented: FHIT gene (3p) (Sozzi et al., 1996) , RB gene (13q) (Mori et al., 1990) , and p53 gene (17p) (Miller et al., 1992) . Although alterations of p16 gene (9p) and APC gene (5q) are infrequently found in SCLCs, other yet unidenti®ed putative tumor suppressor genes on these chromosome arms have been suggested (Hosoe et al., 1994; Kim et al., 1997) .
Recently, several cytogenetic studies indicated that many SCLCs lost 10q, often at the 10q24-qter region suggesting the presence of a tumor-suppressor gene (Ried et al., 1994; Petersen et al., 1997) . To determine the minimal regions of loss on 10q for further positional cloning exercises and to discover the potential role of loss of these tumor-suppressor loci in SCLC tumorigenesis, we studied 46 primary SCLCs using microsatellite analysis. This group of patients comprised 25 men and 21 women ranging in age from 44 ± 80 years (median, 60.3+8.7). The 41 patients whose smoking status was known were heavy smokers. Twenty-one patients (46%) had limited-stage disease at the time of diagnosis, while the other 25 (54%) had extensive disease at the time of diagnosis. Chemotherapy was performed for 43 (93%) of the patients. The survival durations from the date of diagnosis to the date of death range from 1 ± 127 weeks (median, 23 weeks with 95% CI=15, 43).
Because of previous eorts to map candidate tumorsuppressor loci on chromosome 10 in glioblastomas, a large number of microsatellite markers on 10q have been identi®ed. Many of these markers have been physically mapped to precise regions. We selected 11 highly polymorphic microsatellite markers from 10q23 to 10q26 because this region is frequently lost in glioblastoma. Using these microsatellite markers, we analysed the 46 primary SCLCs.
LOH was found in 36 (78%) of the 46 tumors in at least one informative marker tested. Two common minimally deleted regions were noticed. One is located between markers D10S198 and D10S192, a region about 2 cm long. This region was indicated by the LOH patterns in tumors SCLC12 and SCLC13 ( Figure  1 ). Forty-three tumors (93%) were informative in at least one tested marker from D10S185 to D10S168 and 32 (74%) of the 43 tumors exhibited LOH at the region. The other region is between D10S221 and D10S587 (about 11 cm). This region was shown by the LOH patterns of the centromeric breakpoint at the marker D10S221 in tumors SCLC22, SCLC24, SCLC28, and SCLC41 and the telomeric breakpoint at the marker D10S587 in tumors SCLC13 and SCLC32 (Figure 1 ). Forty-four (96%) tumors were informative in at least one tested marker from D10S221 to D10S214 and 29 (66%) of the 44 tumors showed LOH at the region. LOH at all informative markers tested was found in 17 (37%) tumors. Losses of two distinct regions were identi®ed in ®ve tumors (SCLC13, SCLC14, SCLC21, SCLC24 and SCLC29) (Figures 1 and 2) . Loss of both deleted regions together was observed in at least 24 (52%) of the tested SCLCs. One tumor (SCLC46) exhibited LOH only at the most centromeric marker tested (Figure 1) . LOH frequencies at individual markers tested are summarized in Table  1 . In addition, microsatellite instability was found in seven (15%) tumors at a single marker except one of the tumors (SCLC39), in which novel alleles were observed at two microsatellite markers.
LOH on the long arm of chromosome 10 has been identi®ed frequently in glioblastomas, renal cell carcinomas, non-Hodgkin's lymphoma, malignant meningiomas, melanomas, endometrial cancers, and prostate cancers suggesting that at least two putative tumor-suppressor genes exist on this arm (Rasheed et al., 1992; Morita et al., 1991; Speaks et al., 1992; Rempel et al., 1993; Herbst et al., 1994; Peier et al., 1995; Gray et al., 1995) . Recent cytogenetic studies revealed that loss on 10q is also frequent in SCLCs (Ried et al., 1994; Petersen et al., 1997) . Functional analysis by fusion of normal chromosome 10 into glioblastoma cells that had lost a complete copy of chromosome 10 resulted in signi®cantly decreased colony formation in soft agarose and complete suppression of tumor formation in vivo (Pershouse et al., 1993) . These data further support the idea that a tumor-suppressor gene (or genes) is present in chromosome 10.
We analysed the panel of primary SCLCs using closely spaced microsatellite markers in 10q23-q26 and identi®ed two distinct minimally deleted regions on 10q in this tumor type. Seventy-eight per cent (36/46) of the tumors lost at least one of the informative markers tested, and almost 67% of them (24/36) lost two regions or a larger area including the two distinct regions. These ®ndings are consistent with previous reports using cytogenetic means (Ried et al., 1994; Petersen et al., 1997) . Although many of the tumors (17 tumors) exhibited LOH at all informative markers (about 48 cm long indicating a large deletion), the Figure 1 Deletion mapping at chromosome 10q23-q26 in SCLCs. Names of microsatellite markers are at left side of the ®gure and tumors are given on the top of the ®gure. The approximate locations of candidate tumor suppressor genes, PTEN and MXI1 are indicated at right side of the ®gure. For microsatellite analysis, tumors and normal control tissues were dissected under a stereomicroscope. Dissected tissues were digested in 200 ml of 50 mM Tris-HCl (pH 8.0) containing 1% SDS-proteinase K (5 mg/ml) and incubated at 428C for 12 ± 24 h. Digested samples were puri®ed, and DNA was precipitated as described previously (Kim et al., 1997) . One of the primers for each marker was end-labeled with g-32 P-ATP (4500 Ci/mmol; ICN Biomedicals, Costa Mesa, CA) and T4 DNA polynucleotide kinase (New England Biolabs, Beverly, MA). Polymerase chain reaction (PCR) was carried out in 500 ml plastic tubes with containing 20 ng genomic DNA, 1% dimethylsulfoxide, 200 mM dNTP, 1.5 mM MgCl 2 , 0.4 mM PCR primers including 0.01 mM g-32 P-labeled primer and 0.5 units of Taq DNA polymerase (GIBCO ± BRL, Gaithersburg, MD) to a volume of 12.5 ml. DNA was ampli®ed for 35 cycles at 958C for 30 s, 52 ± 608C for 60 s and 708C for 60 s followed by a 5 min extension at 708C. The PCR products were separated on a 6% polyacrylamide gel containing 5.6 M urea and 32% formamide, which was then autoradiographed. LOH was de®ned as a 450% reduction of the intensity by visual inspection in either of the two alleles as compared with intensity of normal control panels. Microsatellite instability was determined by the appearance of unmistakable novel alleles that were not observed in normal tissue control panels other 19 tumors retained at least one of the informative markers tested. Among the 19 tumors, clear deletion breakpoints can be identi®ed in seven tumors (SCLC12, SCLC13, SCLC14, SCLC16, SCLC24, SCLC29 and SCLC32) by the presence of both alleles retained at the markers¯anking the deletion regions (Figures 1 and 2) . The patterns of ®ve tumors (SCLC13, SCLC14, SCLC21, SCLC24, and SCLC29) (Figures 1 and 2) indicate the presence of at least two distinct regions of loss. The markers separating contiguous areas exhibiting LOH are clearly visible, a phenomenon indicating this genetic damage may result from two separate hits. Furthermore, two other tumors (SCLC2 and SCLC34) showed LOH only at markers centromeric to D10S221; the other three tumors (SCLC22, SCLC28 and SCLC41) lost only markers telomeric to D10S221 (Figure 1 ). These data indicate the presence of at least two tumor-suppressor genes at the chromosome segment. It is possible that retention observed between two common deletion areas were in fact a result of homozygous deletion because of the presence of contaminating normal cells in the tumor samples (Cairns et al., 1995) . However, most of the homozygous deletions were small, while the distance between the two common deletion areas was about 15 cm making the possibility unlikely. To further exclude the possibility, we examined 46 SCLC cell lines for possible homozygous deletion using D10S192, D10S168 and D10S221 that showed retention in at least ®ve (11%) of the 46 primary SCLCs and found no evidence of homozygous deletion at these markers (data not shown).
MXI1 is a candidate tumor-suppressor gene identi®ed several years ago and mapped to 10q24-q25 recently (Zervos et al., 1993; Wechsler et al., 1994) . It is a member of HLH-ZIP gene family, which includes at least three other members called Myc, Max and Mad (Blackwood and Eisenman, 1991) . MXI1 can form heterodimers with Max (Wechsler et al., 1994) . These heterodimers may repress transcription by competing with Myc binding sites (Zervos et al., 1993; Ayer et al., 1993) . Therefore, the inactivation of MXI1 may disturb the normal balance, increase the overall activity of Myc oncoprotein, and eventually promote tumorigenesis. The mutations of the gene were identi®ed in four of the ten primary prostate carcinomas in a recent report (Eagle et al., 1995) . These data, together with the fact that more than 74% of the SCLCs lost a region close to MXI1 gene in this study, suggest that the MXI1 gene is an excellent candidate tumor-suppressor gene in SCLCs. To determine whether MXI1 could be inactivated by mutations or homozygous deletions in SCLC, we examined a panel of 16 SCLC cell lines. A normal sized MXI1 PCR product of cDNA including all the coding sequences was obtained in all SCLC cell lines tested suggesting that the expression of the MXI1 gene is not altered in these cell lines (Figure 3 ). To identify potential point mutations in MXI1 gene, all the coding regions of the MXI1 gene and intro-exon boundaries have been sequenced in the 16 SCLC cell lines. No mutations have been noticed. However, two polymorphic regions have been found. One of them is present in one cell line and located in intro 1 involving the 22nd basepair (C?T) upstream of exon 2. The other polymorphism is more frequent (found in ®ve of the 16 cell lines) and located in intro 5 involving deletion of three thymidines from the thymidine trial at the boundary with exon 6. The later polymorphism was con®rmed by analysing genomic DNAs from paired normal tissues and primary SCLCs (Figure 3 ) and could be a useful polymorphic marker for detection of LOH at MXI1 gene. These results suggest that MXI1 does not play a major role in SCLC development.
In glioblastomas, one common deleted region was mapped to 10q23 (Steck et al., 1995; Rasheed et al., D10S108  D10S198  D10S192  D10S168  D10S221  D10S209  D10S587  D10S216  D10S214   18  29  27  24  29  24  35  21  28  20  21 8 (44) 15 (52) 16 (59) 18 (75) 19 (66) 16 (67) 17 (49) 18 (86) 18 (64) 10 (50) 12 (57) 1995). A candidate tumor-suppressor gene called PTEN/MMAC1 located at 10q23 and close to D10S215 was just identi®ed, and mutations of it were found in glioblastoma cell lines, primary glioblastoma and other cancer cell lines including prostate, kidney and breast carcinomas (Steck et al., 1997; Li et al., 1997) . Our data indicate a common deleted region located between D10S198 and D10S192, which is about 17 cm telomeric to the PTEN/MMAC1 gene in SCLCs. This implies that another tumor-suppressor gene dierent from PTEN/MMAC1 may be present. However, in many of our SCLCs a larger area including the PTEN/MMAC1 gene was deleted. One tumor (SCLC46) exhibited LOH only at D10S215 and retained all other informative markers (Figure 1 ). We sequenced all coding region of PTEN/MMAC1 cDNA from 15 SCLC cell lines and did not reveal any mutation or sequence variation, while one other SCLC cell line tested did not express PTEN/MMAC1 suggesting alterations of PTEN/MMAC1 are not frequent in SCLC (Kim et al., 1998) . O 6 -methylguanine-DNA methyltransferase (MGMT) gene was also mapped to 10q24.33-qter (Gardner et al., 1991; Albarosa et al., 1996) . High conservation of the gene product during evolution, its function of repairing the DNA damage caused by mutagenic alkylating agents, and decreased protein activity in some glioblastomas makes MGMT a candidate tumorsuppressor gene. However, no genetic alteration has been reported so far in human tumors.
The second common deleted region identi®ed in this study is between D10S221 and D10S587 at 10q24-q25, 7 RT (GIBCO ± BRL, Gaithersburg, MD). PCR was performed by using primers MXI-6S2 (5'-TCCTGTCGGCCCGAGAAG-3') and MXI-5AS (5'-GTATTGAATTGGCCCAGTG-3') for a MXI1 cDNA fragment including the all coding sequences. (b), a polymorphism located in intro 5 of MXI1 gene is common (four of the six individuals analysed). N indicates normal control DNA and T indicates primary SCLC. Arrows indicate polymorphic alleles. Loss of one gene copy was clearly seen in three of the four tumors (#2, #5, and #6). For sequencing analysis, genomic DNA was extracted from the same 16 SCLC cell lines. Six individual exons of the MXI1 gene were ampli®ed separately. The primers used for amplifying those exons are as follows: exon 1, MXI-6S (5'-TCCCAGGGTAAGGGAGTG-3') and MXI-6AS (5'-CCGAAAAA-GATTAGTATGCGC-3'); exons 2, MXI-1S (5'-AATGGATTTGGGTACTATATTC-3') and MXI-1AS (5'-TTACAGGAGAAAT-GTGCTCC-3'); exon 3, MXI-2S (5'-CTATAGCTTTAGCAACAAAGC-3') and MXI-2AS (5'-AGGTAAAATGGTGAGTTTGC-3'); exons 4, MXI-3S (5'-TGATATTTCTAGTGAAATAACC-3') and MXI-3AS (5'-TATGAATAGGAATCAGTGCC-3'); exon 5, MXI-4S (5'-GTTTTATTGTTTGTACTGGAC-3') and MXI-4AS (5'-CCTTCCCTAAATCCAGATAC-3'); exon 6, MXI-5S (5'-TT-GAAGGTGCGCTATACTC-3') and MXI-5AS. Sequencing primers were the same as the PCR primers except exon 1, for which the primer MXI-6S2 was also used. Ampli®ed DNA and sequencing primers labeled with g-33 P-ATP were subjected to PCR for 30 cycles using the AmpliCycle sequencing kit (Perkin-Elmer, Branchburg, NJ). Each ampli®ed product (3 ml) was run on a 6% Longrange gel (FMC BioProducts, Rockland, ME) and exposed to ®lm a distance of 11 cm. More than 66% of SCLCs in our tumor panel lost this region suggesting the presence of a tumor suppressor gene in the chromosome region. The frequent loss of a similar region was also reported in glioblastomas (Steck et al., 1995; Albarosa et al., 1996) . One report placed the minimal deleted region between D10S587 and D10S216, a distance of approximately 1 cm, in glioblastomas (Albarosa et al., 1996) . Although it is very close to the region we have identi®ed in SCLCs, however, one tumor (SCLC13) exhibited a clear loss at D10S209 while the allele was retained at D10S221 and D10S587 ( Figure  2 ). This indicated that a candidate tumor-suppressor gene may be located at or more centromeric to the marker D10S587. Alternatively, part of the putative gene may be located between D10S587 and D10S216 because the deletion of one part of the gene (presumably centromeric to D10S587) might be sucient to inactivate its tumor-suppressor function. In fact, a candidate tumor suppressor gene, DMBT1, was recently mapped between markers D10S209 and D10S587 (Mollenhauer et al., 1997) . Homozygous deletion of the gene has been found in a signi®cant number of high grade brain tumors (Mollenhauer et al., 1997) suggesting DMBT1 may play an important role in brain tumor progression. Potential presence of DMBT1 alterations and their role in SCLC are currently under investigation.
